Next Generation Fecal Microbiota Transplantation
2
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
Fecal microbiota transplantation (FMT) is considered as an effective treatment for Clostridioides difficile infection. However, theprecise mechanism of FMT is yet to be determined. Human stool consists of the gut microbiota, bacterial debris, and metabolicproducts. Of these, the intestinal microbiota is the most important factor that exerts therapeutic efficacy in FMT. Fresh donor stool,blended with normal saline, has been employed for traditional FMT. Nevertheless, stool processing is a major impediment in FMT. Frozen stool and capsule formulations have similar efficacy to that of fresh stool. In addition, several novel stool products havebeen identified. A stool bank that provides stool products with pre-screened donor stool has been established to help physiciansand thereby facilitate FMT. Recent next-generation sequencing techniques have been key in facilitating the detailed analysis of themicrobiota and gut environment of individual donors and recipients.
Abstract
Fecal microbiota transplantation (FMT) is considered as an effective treatment for Clostridioides difficile infection. However, theprecise mechanism of FMT is yet to be determined. Human stool consists of the gut microbiota, bacterial debris, and metabolicproducts. Of these, the intestinal microbiota is the most important factor that exerts therapeutic efficacy in FMT. Fresh donor stool,blended with normal saline, has been employed for traditional FMT. Nevertheless, stool processing is a major impediment in FMT. Frozen stool and capsule formulations have similar efficacy to that of fresh stool. In addition, several novel stool products havebeen identified. A stool bank that provides stool products with pre-screened donor stool has been established to help physiciansand thereby facilitate FMT. Recent next-generation sequencing techniques have been key in facilitating the detailed analysis of themicrobiota and gut environment of individual donors and recipients.
참고문헌 (30)
- Quraishi MN, "Systematic review with meta-analysis : the efficacy of faecal microbiota transplantation for the treatment of recurrent and refractory Clostridium difficile infection", Aliment Pharmacol Ther, 46, pp.479~493 (2017)
- Brandt LJ, "Long-term follow-up of colonoscopic fecal microbiota transplant for recurrent Clostridium difficile infection", Am J Gastroenterol, 107, pp.1079~1087 (2012)
- Kyeong Ok Kim, "Fecal Microbiota Transplantation: An Update on Clinical Practice", Clinical Endoscopy, 52(2), pp.137~143 (2019), 대한소화기내시경학회[DOI]
- Burz SD, "A guide for Ex Vivo handling and storage of stool samples intended for fecal microbiota transplantation", Sci Rep, 9, pp.8897~ (2019)
- Hamilton MJ, "Standardized frozen preparation for transplantation of fecal microbiota for recurrent Clostridium difficile infection", Am J Gastroenterol, 107, pp.761~767 (2012)
- Costello SP, "Faecal microbiota transplant for recurrent Clostridium difficile infection using long-term frozen stool is effective : clinical efficacy and bacterial viability data", Aliment Pharmacol Ther, 42, pp.1011~1018 (2015)
- Lee CH, "Frozen vs Fresh fecal microbiota transplantation and clinical resolution of diarrhea in patients with recurrent Clostridium difficile infection : a randomized clinical trial", JAMA, 315, pp.142~149 (2016)
- Terveer EM, "How to : establish and run a stool bank", Clin Microbiol Infect, 23, pp.924~930 (2017)
- Kim KO, "Reducing cost and complexity of fecal microbiota transplantation using universal donors for recurrent Clostridium difficile infection", Adv Ther, 36, pp.2052~2061 (2019)
- Wang S, "Systematic review : adverse events of fecal microbiota transplantation", PLoS One, 11, pp.e0161174~ (2016)
- Youngster I, "Oral, capsulized, frozen fecal microbiota transplantation for relapsing Clostridium difficile infection", JAMA, 312, pp.1772~1778 (2014)
- Kao D, "Effect of oral capsule-vs colonoscopy-delivered fecal microbiota transplantation on recurrent clostridium difficile infection : a randomized clinical trial", JAMA, 318, pp.1985~1993 (2017)
- Bar-Yoseph H, "Oral capsulized fecal microbiota transplantation for eradication of carbapenemase-producing Enterobacteriaceae colonization with a metagenomic perspective", Clin Infect Dis (2020)
- Jiang ZD, "Safety and preliminary efficacy of orally administered lyophilized fecal microbiota product compared with frozen product given by enema for recurrent Clostridium difficile infection : a randomized clinical trial", PLoS One, 13, pp.e0205064~ (2018)
- Reigadas E, "Faecal microbiota transplantation for recurrent Clostridioides difficile infection : experience with lyophilized oral capsules", J Hosp Infect, 105, pp.319~324 (2020)
- Reygner J, "Freeze-dried fecal samples are biologically active after long-lasting storage and suited to fecal microbiota transplantation in a preclinical murine model of Clostridioides difficile infection", Gut Microbes, 11, pp.1405~1422 (2020)
- Jiang ZD, "Randomised clinical trial : faecal microbiota transplantation for recurrent Clostridum difficile infection-fresh, or frozen, or lyophilised microbiota from a small pool of healthy donors delivered by colonoscopy", Aliment Pharmacol Ther, 45, pp.899~908 (2017)
- DeFilipp Z, "Drug-resistant E. coli bacteremia transmitted by fecal microbiota transplant", N Engl J Med, 381, pp.2043~2050 (2019)
- Petrof EO, "Stool substitute transplant therapy for the eradication of Clostridium difficile infection : ‘RePOOPulating’the gut", Microbiome, 1, pp.3~ (2013)
- Ott SJ, "Efficacy of sterile fecal filtrate transfer for treating patients with Clostridium difficile infection", Gastroenterology, 152, pp.799~811 (2017)
- Papanicolas LE, "Bacterial viability in faecal transplants : which bacteria survive?", EBioMedicine, 41, pp.509~516 (2019)
- Costello SP, "Effect of fecal microbiota transplantation on 8-week remission in patients with ulcerative colitis : a randomized clinical trial", JAMA, 321, pp.156~164 (2019)
- Imdad A, "Fecal transplantation for treatment of inflammatory bowel disease", Cochrane Database Syst Rev, 11, pp.Cd012774~ (2018)
- Mullish BH, "The use of faecal microbiota transplant as treatment for recurrent or refractory Clostridium difficile infection and other potential indications : joint British Society of Gastroenterology(BSG)and Healthcare Infection Society(HIS)guidelines", Gut, 67, pp.1920~1941 (2018)
- Gerding DN, "Administration of spores of nontoxigenic Clostridium difficile strain M3 for prevention of recurrent C. difficile infection : a randomized clinical trial", JAMA, 313, pp.1719~1727 (2015)
- Khanna S, "A Novel Microbiome therapeutic increases gut microbial diversity and prevents recurrent Clostridium difficile infection", J Infect Dis, 214, pp.173~181 (2016)
- Henn MR, "A phase 1b safety study of SER287, a spore-based microbiome therapeutic, for active mild to moderate ulcerative colitis", Gastroenterology, 160, pp.115~127 (2021)
- Li SS, "Durable coexistence of donor and recipient strains after fecal microbiota transplantation", Science, 352, pp.586~589 (2016)
- Paramsothy S, "Specific bacteria and metabolites associated with response to fecal microbiota transplantation in patients with ulcerative colitis", Gastroenterology, 156, pp.1440~1454 (2019)
- Moayyedi P, "Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial", Gastroenterology, 149, pp.102~109 (2015)